Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and Quality Management

Veeva Systems Inc.
Posted on: 23 Aug 16

Veeva Systems (NYSE:VEEV) today announced that Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) based in Japan, selected Veeva Vault eTMF, Veeva Vault QualityDocs, and Veeva Vault Submissions to unify content management throughout its research and development (R&D) operations worldwide.

The unique multitenant cloud capabilities of Veeva Vault enable Daiichi Sankyo to easily streamline management of its critical content, providing external partners, such as CROs, the same level of secure access and collaboration as internal operations teams. Another key benefit was the ability of Veeva’s support organization to implement Veeva Vault in a short period of time to drive greater consistency globally at every stage of product development, from clinical to quality to regulatory.

“Veeva Vault was superior to every solution we evaluated in the market,” said Yasuhiro Ikeda, the Vice President, IT Strategy Department. “Veeva gives us a true cloud platform to stay current on the latest technology capabilities. With Veeva conducting installation qualification (IQ) and operational qualification (OQ) processes, we expect to save resources and costs not having to upgrade projects every several years. Lastly, Veeva provided a sandbox environment during our selection phase for users to test technical and business capabilities. The high satisfaction among our users was one of the deciding factors in selecting Veeva.”

“Veeva Vault makes it easier for pharmaceutical companies based in Japan to accelerate their global efforts,” said Takashi Okamura, general manager of Veeva Japan. “We are honored to globally support Daiichi Sankyo and deliver greater visibility, transparency, and efficiency in their global pharmaceutical operations.”

Additional Information

For more on Veeva Vault, visit:
Stay updated on the latest Veeva news on LinkedIn:
Follow @veevasystems on Twitter:
Like Veeva on Facebook:

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 400 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2016. This is available on the company’s website at under the Investors section and on the SEC’s website at Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

View source version on

Business Wire

Last updated on: 23/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.